N/A N=205 Depression Attention for Women Now (The DAWN Study)
Depressive Disorder
Primary: Depression Treatment Outcome — 0.96; 1.33 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=504 MDD POC Study GSK372475 Subjects Depressive Disease
Depressive Disorder
Primary: Mean Change From Randomization at the End of the Treatment Phase in the MADRS Total Score — -16.9; -19.0; -20.5 Score on scale — p=0.485
Phase 3 N=211 Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose
Major Depressive Disorder With Mixed Features
Primary: Mean Change From Baseline to the 6-week Study Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Scores — -20.5; -13.0 units on a scale — p=<0.0001
N/A N=9 European Deep Brain Stimulation (DBS) Depression Study
Depressive Disorder, Major
Primary: Mean Percent Change From Baseline in MADRS Score — -7.7; -7.4; -8.8; -6.2 percentage change from baseline
Phase 3 N=569 A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)
Depressive Disorder, Major
Primary: Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8/Withdrawal — -13.9; -14.4; -12.9 Scores on a scale — p=0.853
Phase 2 N=16 Double-blind Pilot Trial of Mirtazapine for the Treatment of Co-occurring AD/MDD.
Major Depressive Disorder · Alcohol Use Disorder
Primary: Drinks Per Drinking Day — 3.5; 4.4 Drinks per drinking day
N/A N=5,325 Digital Detection of Dementia (D Cubed) Studies: D2
Alzheimer Disease and Related Dementias (ADRD)
Primary: 12-Month Cumulative Incidence of ADRD Diagnoses — 213; 134; 355 Number of new ADRD cases — p=0.006
Phase 2 N=769 Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder
Major Depressive Disorder
Primary: Change From the End of Phase A (Week 8 Visit) to the End of Phase B (Week 14 Visit) in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score. — -8.20; -7.02…
Phase 4 N=55 MiDAS II (Mild® Decompression Alternative to Open Surgery): Vertos Mild Patient Evaluation Study
Lumbar Spinal Stenosis
Primary: Changes in Back Pain as Measured by a 10-point Visual Analog Scale (VAS). — 3.59 units on a scale — p=<0.0001
Phase 4 N=480 Study Comparing Discontinuation Symptoms Of DVS SR In Subjects With Major Depressive Disorder (MDD)
Major Depressive Disorder
Primary: Total Discontinuation - Emergent Signs and Symptoms (DESS) Score Over the First 2 Weeks of the Double-blind Phase — 4.1; 4.8; 5.3 scores on a scale
Phase 2 N=7 Treatment of Young Adults With Comorbid AUD/MDD: A Pilot Medication Trial
Major Depressive Disorder · Alcohol Use Disorder
Primary: Drinks Per Drinking Day — 2.8; 2.0 Drinks per drinking day
Phase 3 N=598 Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder
Major Depressive Disorder
Primary: Change From Baseline to Week 8 in DSST (Number of Correct Symbols) and RAVLT (Acquisition and Delayed Recall) Using the Composite Z-score Defined as the Weighted Sum of…
Phase 3 N=480 Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Major Depressive Disorder
Primary: Montgomery-Asberg Depression Rating Scale — -14.7; -10.2 units on a scale — p=<0.0001
N/A N=851 Study Comparing Remission Rates, in Patients With Major Depressive Disorder (MDD)
Major Depressive Disorder
Primary: Percentage of Participants With Remission Based on Hamilton Depression Scale (HAM-D) — 54.4 Percentage of participants
Phase 3 N=150 TRIAD - Treatment of Insomnia and Depression
Sleep Initiation and Maintenance Disorders · Depression
Primary: Percent of Participants With Depression Remission — 36.0; 43.8 percentage of participants in arm
Phase 4 N=924 Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)
Major Depressive Disorder
Primary: Change From Baseline on the Hamilton Rating Scale for Depression, 17-item Total Score (HAM-D17) at Week 8 — -9.71; -11.28; -11.67 Units on a scale — p=0.006
Phase 4 N=85 Advancing Personalized Antidepressant Treatment Using PET/MRI
Depression
Primary: Change From Baseline in Hamilton Depression Rating Scale at 8 Weeks — 11.81; 9.41 score on a scale
Phase 2 N=22 Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD)
Anxious Major Depressive Disorder
Primary: Hamilton Rating Scale for Depression (HAM-D) Total Score. — 14.249; 16.307 Units on a scale
Phase 2 N=273 A Phase 2 Trial of OPC-64005 for Major Depressive Disorder
Major Depressive Disorder
Primary: Mean Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Week 6 of the Double-blind Treatment Period — -1.9; -1.6; -2.1; -3.9 Units…
Phase 3 N=363 A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Major Depressive Disorder
Primary: Change From Baseline to Week 8 in the Children's Depression Rating Scale, Revised (CDRS-R) Total Score (n=102, 104, 106) — -22.85; -23.70; -24.37 Score on a scale…
Phase 2 N=177 Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant
Major Depressive Disorder
Primary: Change From Augmentation Baseline for Non-Remitters in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score at Week 6 - Last Observation Carried Forward (LOCF)…
Phase 3 N=48 Major Depressive Disorder With Mixed Features - Extension
Major Depressive Disorder
Primary: Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs) — 66.7 percentage of subjects
Phase 4 N=78 MiDAS I (Mild® Decompression Alternative to Open Surgery): Vertos Mild Patient Evaluation Study
Lumbar Spinal Stenosis
Primary: Mean Change in Back Pain as Measured by a 10-point Visual Analog Scale (VAS). — 3.21 units on a scale — p=<0.0001
N/A N=386 Trial to Evaluate the Effectiveness of a Digital Therapeutics in Adults Diagnosed With Major Depressive Disorder
Major Depressive Disorder
Primary: Change From Baseline to Week 6 in the MADRS Total Score — -9.03; -7.25 score on a scale — p=0.0568
Phase 4 N=68 Cost- Effectiveness and Quality of Life Assessment in Major Depression Disorder
Depression
Primary: Number of Participants With Response to Treatment — 58 Participants
N/A N=30 Intensive tDCS for MDD: Feasibility Study
Major Depressive Disorder
Primary: Change in Depressive Symptoms Measured by the Patient Health Questionnaire (PHQ-9) — 21; 31.5 percentage of change
Phase 3 N=327 A Trial of AXS-05 in Patients With Major Depressive Disorder
Depression · Major Depressive Disorder
Primary: Change in MADRS Total Score From Baseline to Week 6 — 15.91; 12.04 score on a scale — p=0.002
N/A N=138 MiDAS III (Mild® Decompression Alternative to Open Surgery): Vertos Mild Patient Evaluation Study
Lumbar Spinal Stenosis
Primary: Percentage of Participants With a 2-point Improvement in Visual Analogue Scale — 65.71; 46.15 percentage of responders
Phase 2 N=62 Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD
Depressive Disorder, Major · Depressive Disorder, Treatment-Resistant
Primary: Incidence of Treatment Emergent Adverse Events (AEs) [Safety and Tolerability] — 9; 15; 12; 0 Participants
Phase 2 N=54 Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)
Depression
Primary: Part 1: Number of Participants With Moderate Intensity Adverse Events (AEs) — 2; 0; 1; 2 participants